Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

43.54 -0.46 (-1.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Where Ionis Pharmaceuticals Stands With Analysts ↗

November 17, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

October 23, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

September 27, 2023

Via Benzinga

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies ↗

December 27, 2023

These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024.

Via InvestorPlace

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout. ↗

December 19, 2023

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

November 16, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent? ↗

November 10, 2023

Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout.

Via Chartmill

Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat ↗

November 02, 2023

Via Benzinga

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗

October 17, 2023

Via Benzinga

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 02, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Why Ionis Pharmaceuticals Stock Popped Today ↗

September 26, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant...

Via Benzinga

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action ↗

September 26, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents...

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action

September 26, 2023

Via Investor Brand Network

The 7 Most Hated Stocks by Institutional Traders ↗

September 20, 2023

Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future.

Via InvestorPlace

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,

Via Benzinga

Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports ↗

August 07, 2023

Via Benzinga

Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗

July 31, 2023

Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 31, 2023

Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58...

Via Benzinga

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗

July 17, 2023

The companies are working on treatments for a leading cause of heart failure.

Via Investor's Business Daily

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.